Skip to content

Reported May 6, 2025 · After market close

Revenue estimate$19.7M
EPS estimate-$0.51

Next report

Aug 4, 2026 (in a month)
Revenue estimate$31.5M
EPS estimate-$0.62

Financials

Q1 2025

Income statement

See full
Revenue$17.6M+36.4%
Gross profit$9.0M+24.6%
Operating income-$18.6M-97.2%
Net income-$28.7M-130%
EPS (diluted)-$0.93+55.1%

Balance sheet

See full
Cash & equivalents$42.5M+92.3%
Total debt$7.0M
Total equity$313.8M+246%
Total assets$338.0M

Cash flow

See full
Operating cash flow-$20.0M-64.5%
CapEx$333.0K-18.0%
Free cash flow-$20.3M-61.8%

Valuation & ratios

Profitability

See full
Gross margin53.9%-0.5pp
Operating margin-78%-27.0pp
Net margin-101.6%-34.3pp
FCF margin-85.1%-28.3pp

Returns & leverage

See full
Debt / equity
Current ratio15.9×

Segments

By product

See full
I Let$9.6M-7.2%
Single Use Products$4.2M+142%

By geography

See full
Non Us-

Versus estimates

Ask the moment Beta Bionics, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Beta Bionics, Inc. Common Stock report Q1 2025 earnings?
Beta Bionics, Inc. Common Stock (BBNX) reported Q1 2025 earnings on May 6, 2025 after market close.
What were Beta Bionics, Inc. Common Stock's Q1 2025 revenue and EPS?
Beta Bionics, Inc. Common Stock reported revenue of $17.6M and diluted EPS of $-0.52 for Q1 2025.
Did Beta Bionics, Inc. Common Stock beat estimates in Q1 2025?
Revenue missed the consensus estimate of $19.7M by $2.0M. EPS missed the consensus estimate of $-0.51 by $0.01.
Where can I find Beta Bionics, Inc. Common Stock's Q1 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-064504) directly on SEC EDGAR. The filing index links above go to sec.gov.